Use of the ADAMTS13 activity assay improved the accuracy and efficiency of the diagnosis and treatment of suspected acquired thrombotic thrombocytopenic purpura

Archives of Pathology and Laboratory Medicine

Volumn 138, Issue 4, 2014, Pages 546-549

  Barrows, Brad D ^a   Teruya, Jun ^a,b  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b TEXAS CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADAM PROTEIN; ADAMTS13 PROTEIN, HUMAN;

ARTICLE; BLOOD; BLOOD ANALYSIS; CHILD; ENZYMOLOGY; EVALUATION STUDY; FLUORESCENCE RESONANCE ENERGY TRANSFER; HUMAN; METHODOLOGY; PLASMAPHERESIS; RETROSPECTIVE STUDY; THROMBOTIC THROMBOCYTOPENIC PURPURA;

ADAM PROTEINS; BLOOD CHEMICAL ANALYSIS; CHILD; FLUORESCENCE RESONANCE ENERGY TRANSFER; HUMANS; PLASMA EXCHANGE; PURPURA, THROMBOTIC THROMBOCYTOPENIC; RETROSPECTIVE STUDIES;

EID: 84898402875     PISSN: 00039985     EISSN: 15432165     Source Type: Journal    
DOI: 10.5858/arpa.2013-0170-OA     Document Type: Article

References (29)

1. Moschcowitz E. Hyaline thrombosis of the terminal arterioles and capillaries: a hitherto undescribed disease. Proc N Y Pathol Soc. 1924;24(1): 21-24.
2. George JN, Al-Nouri ZL. Diagnostic and therapeutic challenges in the thrombotic thrombocytopenic purpura and hemolytic uremic syndromes. Hematology Am Soc Hematol Educ Program. 2012;2012(1):604-609.
3. Cerma'ková Z, Hrdliková R, Sula'ková T, Koŕstka M, Kova'rová P, Hrachovinová I. Thrombotic thrombocytopenic purpura: incidence of congenital form of disease in north Moravia (region Moravia-Silesia). Prague Med Rep. 2009; 110(3):239-244.
4. Scully M, Yarranton H, Liesner R, et al. Regional UK TTP registry: correlation with laboratory ADAMTS13 analysis and clinical features. Br J Haematol. 2008;142(5):819-826.
5. Terrell DR, Williams LA, Vesely SK, Lammle B, Hovinga JA, George JN. The incidence of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: all patients, idiopathic patients, and patients with severe ADAMTS-13 deficiency. J Thromb Haemost. 2005;3(7):1432-1436.
6. Moake JL. Thrombotic microangiopathies. N Engl J Med. 2002;347(8):589- 600.
7. Furlan M, Robles R, Lammle B. Partial purification and characterization of a protease from human plasma cleaving von Willebrand factor to fragments produced by in vivo proteolysis. Blood. 1996;87(10):4223-4234.
8. Furlan M, Robles R, Solenthaler M, Wassmer M, Sandoz P, Lammle B. Deficient activity of vonWillebrand factor-cleaving protease in chronic relapsing thrombotic thrombocytopenic purpura. Blood. 1997;89(9):3097-3103.
9. Tsai HM. Physiologic cleavage of von Willebrand factor by a plasma protease is dependent on its conformation and requires calcium ion. Blood. 1996;87(10):4235-4244.
10. Pineda AA, Vamvakas EC. Applications of therapeutic apheresis in patients with malignant disease. Oncologist. 1997;2(2):94-103.
11. Amorosi EL, Ultmann JE. Thrombotic thrombocytopenic purpura: report of 16 cases and review of the literature. Medicine (Baltimore). 1966;45(2):139-160.
12. Rock GA, Shumak KH, Buskard NA, et al. Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura: Canadian Apheresis Study Group. N Engl J Med. 1991;325(6):393-397.
13. Clark WF, Rock GA, Buskard N, et al. Therapeutic plasma exchange: an update from the Canadian Apheresis Group. Ann Intern Med. 1999;131(6):453- 462.
14. Mokrzycki MH, Kaplan AA. Therapeutic plasma exchange: complications and management. Am J Kidney Dis. 1994;23(6):817-827.
15. Bagot KL, Bove LL, Masser BM, Bednall TC, Buzza M. Perceived deterrents to being a plasmapheresis donor in a voluntary, nonremunerated environment. Transfusion. 2013;53(5):1108-1119.
16. Wahl PM, Bohn RL, Terrell DR, George JN, Ewenstein B. Health care utilization of patients diagnosed with idiopathic thrombotic thrombocytopenic purpura in a commercially insured population in the United States. Transfusion. 2012;52(7, pt 2):1614-1621.
17. Just S. Methodologies and clinical utility of ADAMTS-13 activity testing. Semin Thromb Hemost. 2010;36(1):82-90.
18. Ko S, Okano E, Kanehiro H, et al. Plasma ADAMTS13 activity may predict early adverse events in living donor liver transplantation: observations in 3 cases. Liver Transpl. 2006;12(5):859-869.
19. Ono T, Mimuro J, Madoiwa S, et al. Severe secondary deficiency of von Willebrand factor-cleaving protease (ADAMTS13) in patients with sepsis-induced disseminated intravascular coagulation: its correlation with development of renal failure. Blood. 2006;107(2):528-534.
20. Song J, Lee KA, Park TS, Park R, Choi Jr. Linear relationship between ADAMTS13 activity and platelet dynamics even before severe thrombocytopenia. Ann Clin Lab Sci. 2008;38(4):368-375.
21. Crist RA, Rodgers GM. A comparison of two commercial ADAMTS13 activity assays with a reference laboratory method. Lab Med. 2009;40(4):232- 235.
22. Benhamou Y, Assie C, Boelle PY, et al. Development and validation of a predictive model for death in acquired severe ADAMTS13 deficiency-associated idiopathic thrombotic thrombocytopenic purpura: the French TMA Reference Center experience. Haematologica. 2012;97(8):1181-1186.
23. Lotta LA, Wu HM, Musallam KM, Peyvandi F. The emerging concept of residual ADAMTS13 activity in ADAMTS13-deficient thrombotic thrombocytopenic purpura. Blood Rev. 2013;27(2):71-76.
24. Steele M, Chen HH, Steele J, Chan AK, Lau KK. Thrombotic thrombocytopenic purpura in pediatric patients. Zhongguo Dang Dai Er Ke Za Zhi. 2012; 14(11):803-810.
25. Zuber J, Fakhouri F, Roumenina LT, Loirat C, Fr'emeaux-Bacchi V; French Study Group for aHUS/C3G. Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies. Nat Rev Nephrol. 2012;8(11):643-657.
26. Furlan M, Robles R, Galbusera M, et al. von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. N Engl J Med. 1998;339(22):1578-1584.
27. Tsai HM, Lian EC. Antibodies to vonWillebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med. 1998;339(22):1585- 1594.
28. Kremer Hovinga JA, Lammle B. Role of ADAMTS13 in the pathogenesis, diagnosis, and treatment of thrombotic thrombocytopenic purpura. Hematology Am Soc Hematol Educ Program. 2012;2012(1):610-616.
29. Froehlich-Zahnd R, George JN, Vesely SK, et al. Evidence for a role of anti- ADAMTS13 autoantibodies despite normal ADAMTS13 activity in recurrent thrombotic thrombocytopenic purpura. Haematologica. 2012;97(2):297-303.